CA3214228A1 - Transdermal delivery of cannabidiol - Google Patents
Transdermal delivery of cannabidiol Download PDFInfo
- Publication number
- CA3214228A1 CA3214228A1 CA3214228A CA3214228A CA3214228A1 CA 3214228 A1 CA3214228 A1 CA 3214228A1 CA 3214228 A CA3214228 A CA 3214228A CA 3214228 A CA3214228 A CA 3214228A CA 3214228 A1 CA3214228 A1 CA 3214228A1
- Authority
- CA
- Canada
- Prior art keywords
- days
- once
- pain
- transdermal
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/227,591 US12121617B2 (en) | 2019-10-14 | 2021-04-12 | Transdermal delivery of cannabidiol |
| US17/227,591 | 2021-04-12 | ||
| PCT/IB2022/053276 WO2022219468A1 (en) | 2021-04-12 | 2022-04-07 | Transdermal delivery of cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3214228A1 true CA3214228A1 (en) | 2022-10-20 |
Family
ID=83640369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3214228A Pending CA3214228A1 (en) | 2021-04-12 | 2022-04-07 | Transdermal delivery of cannabidiol |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4322931A4 (https=) |
| JP (1) | JP2024513961A (https=) |
| CN (1) | CN117460503A (https=) |
| AU (1) | AU2022257344A1 (https=) |
| CA (1) | CA3214228A1 (https=) |
| MX (1) | MX2023011948A (https=) |
| WO (1) | WO2022219468A1 (https=) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2760460C (en) * | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| EP2424568A1 (en) * | 2009-04-29 | 2012-03-07 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| HK1244715A1 (zh) * | 2015-03-02 | 2018-08-17 | 阿福金制药有限责任公司 | 用大麻素的局部区域神经影响性疗法 |
| US10272125B2 (en) * | 2015-09-14 | 2019-04-30 | Life Tech Global, Llc | Transdermal delivery of cannabidiol with other active moieties including cannabinoids |
| JP2020530857A (ja) * | 2017-08-14 | 2020-10-29 | ジナーバ・ファーマシューティカルズ・インコーポレイテッド | 経皮カンナビジオールゲルを用いた変形性関節症の治療方法 |
| CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
| US12357604B2 (en) * | 2017-09-22 | 2025-07-15 | Inmed Pharmaceuticals Inc. | Topical formulations of cannabinoids and use thereof in the treatment of pain |
| BR112020014253A2 (pt) * | 2018-01-12 | 2020-12-08 | Nutrae, LLC | Formulações de canabinóides encapsuladas para administração oral |
| KR20220044558A (ko) * | 2019-08-05 | 2022-04-08 | 씨에스 메디카 에이/에스 | 칸나비디올을 포함하는 외용 제제, 조성물의 제조 방법 및 이의 용도 |
| EP4041209A4 (en) * | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| CA3155181A1 (en) * | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| CA3178878A1 (en) * | 2020-04-20 | 2021-10-28 | Fotios M. Plakogiannis | Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain |
| WO2022003623A1 (en) * | 2020-07-01 | 2022-01-06 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations for the treatment of multiple sclerosis |
| US20220047525A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids |
| CN117337174A (zh) * | 2020-12-03 | 2024-01-02 | 长矛治疗股份有限公司 | 用于治疗癌症的包含cbd或thc的透皮药物制剂 |
| AU2022255944A1 (en) * | 2021-04-08 | 2023-10-12 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
-
2022
- 2022-04-07 AU AU2022257344A patent/AU2022257344A1/en not_active Abandoned
- 2022-04-07 EP EP22787716.4A patent/EP4322931A4/en not_active Withdrawn
- 2022-04-07 CN CN202280041627.4A patent/CN117460503A/zh active Pending
- 2022-04-07 MX MX2023011948A patent/MX2023011948A/es unknown
- 2022-04-07 WO PCT/IB2022/053276 patent/WO2022219468A1/en not_active Ceased
- 2022-04-07 CA CA3214228A patent/CA3214228A1/en active Pending
- 2022-04-07 JP JP2023562593A patent/JP2024513961A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022257344A1 (en) | 2023-10-26 |
| JP2024513961A (ja) | 2024-03-27 |
| CN117460503A (zh) | 2024-01-26 |
| EP4322931A4 (en) | 2025-03-12 |
| MX2023011948A (es) | 2023-10-17 |
| WO2022219468A1 (en) | 2022-10-20 |
| EP4322931A1 (en) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020366147B2 (en) | Transdermal delivery of cannabidiol | |
| US12121617B2 (en) | Transdermal delivery of cannabidiol | |
| US20250248948A1 (en) | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | |
| AU2020361741B2 (en) | Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders | |
| US20260076921A1 (en) | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | |
| AU2020358869A1 (en) | Transdermal delivery of dronabinol | |
| US20240261235A1 (en) | Pharmaceutical Composition And Method For Treating Seizure Disorders | |
| CA3213953A1 (en) | Pharmaceutical composition and method for treating seizure disorders | |
| EP4326252A1 (en) | Transdermal pharmaceutical formulations for the treatment of chronic pain | |
| US12268699B2 (en) | Transdermal delivery of tetrahydrocannabinol | |
| CA3214228A1 (en) | Transdermal delivery of cannabidiol | |
| WO2026018119A1 (en) | Transdermal delivery of tetrahydrocannabinol | |
| US20250049821A1 (en) | Pharmaceutical Composition and Method for Treating Seizure Disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250328 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |